pindolol has been researched along with Experimental Leukemia in 2 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sytkowski, AJ | 1 |
| Kessler, CJ | 1 |
| D'Albis, JN | 1 |
| Kassis, S | 1 |
| Lauter, CJ | 1 |
| Stojanov, M | 1 |
| Salem, N | 1 |
2 other studies available for pindolol and Experimental Leukemia
| Article | Year |
|---|---|
Adenylate cyclase coupled beta adrenergic receptors of Rauscher erythroleukemia cells.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Animals; Cell Line; Cell Membrane; Clone Cells; Cycl | 1981 |
Exfoliation of the beta-adrenergic receptor and the regulatory components of adenylate cyclase by cultured rat glioma C6 cells.
Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; A | 1986 |